The Greater Cannabis Company, Inc. (GCAN)
|Net Income (ttm)||-951,170|
|Trading Day||May 13|
|Day's Range||0.0076 - 0.0080|
|52-Week Range||0.0018 - 0.0241|
BALTIMORE, March 16, 2021 (GLOBE NEWSWIRE) -- Greater Cannabis Company ( OTCQB: GCAN ), an innovator in the development and commercialization of cannabinoid delivery systems and cannabinoid products is ...
BALTIMORE, MD, Jan. 20, 2021 (GLOBE NEWSWIRE) -- The Greater Cannabis Company (GCAN), an innovator in the development and commercialization of cannabinoid delivery systems and cannabinoid products today...
The Greater Cannabis Company, Inc., a biopharmaceutical company, focuses on the development and commercialization of technology for transmucosal delivery of legal medical or recreational cannabis and cannabinoids. The company's initial product is an oral transmucosal patch platform, which provides loaded actives to be absorbed by the buccal mucosa into the body. It intends to commercialize the technology by sublicensing or partnering with licensed producers, distributors, processors, consumer product, and pharmaceutical companies. The company w... [Read more...]
Drug Manufacturers-Specialty & Generic
|Stock Exchange |
|Ticker Symbol |
In 2020, GCAN's revenue was $48,044, an increase of 574.78% compared to the previous year's $7,120. Losses were -$951,170, -42.30% less than in 2019.